202 - The Final Rule: The Implications of the New Clinical Measures on the Care of the CKD Patient

Note - This session is a total of 45 minutes, and therefore .75 contact hours; however, the CNE evaluation for this session includes a reflection that you must complete (questions are required) that allows you an extra .25 contact hours - bringing your contact hour total for this session to 1.00.

Contact hours available until 4/16/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure:
Speakers have no disclosures to declare.

Planning Committee:
• Annette Hood discloses that she is a member of the Amgen speakers’ bureau.
• Denise Murcek discloses other financial/material support as an employee of the VA Medical Center.
• Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care.
• Kyra Trappett discloses other financial/material support as an employee of DaVita.

Commercial Support and Sponsorship:
Supported by an educational grant from Sanofi Renal

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:
• Describe the provisions of the final rule for the prospective payment system.
• Discuss the impact of the PPS provisions on dialysis services.
• Analyze the risk factors and laboratory values that can impact the development of hypercalcemia in the CKD patient.
• Recognize effective treatment strategies to minimize hypercalcemia in the individual with CKD or incident to hemodialysis/peritoneal dialysis.